A study found that the expression of miR-155 and the mutation of the gene MyD88 are increased in patients with diffuse large B-cell lymphoma (DLBCL), and the mutation impacts disease progression and prognosis. This study was published in the Journal of Experimental Hematology.
To conduct this study, researchers assessed 135 cases of DLBCL, and 90 cases of reactive hyperplasia of lymph nodes were used as a control.
According to the results, the relative expression of miR-155 in patients with DLBCL was markedly higher compared to the control group (P<0.05). The results also showed that mutation rate of MyD88 L265P in the DLBCL group was notably higher than that of control group (P<0.05).
The investigators concluded that “the abnormal expression of miR-155 and the mutation rate of MyD88 gene in DLBCL patients are increased, and the expression of miR-155 and the mutation of MyD88 gene affect the disease progression and prognosis of patients, which may be potential biological indicators for the diagnosis, treatment and prognosis of DLBCL.”
Link: https://pubmed.ncbi.nlm.nih.gov/34105469/
Keywords: miR-155, MyD88, target gene, diffuse large B-cell lymphoma
